GHK-Cu Safety Signals & FDA Actions: What Patients and Prescribers Need to Know

Is any GHK-Cu product FDA-approved?

No FDA-approved drug is known to contain GHK-Cu [1]. Whether a topical copper peptide product is a cosmetic or a drug depends on its intended use: a claim to treat disease, or to affect the structure or function of the body, makes it a drug under the law [2]. Cosmetic ingredients other than color additives do not need FDA approval before sale, so copper peptide serums and creams sold as cosmetics need no approval [2]. An injectable GHK-Cu product is not a cosmetic, and it is not FDA-approved [2].

One naming trap: copper histidinate (Zycubo) was approved on January 12, 2026 for Menkes disease in children. It is a different compound from GHK-Cu [1][9].

What FDA has said about the non-injectable form

Topical GHK-Cu appears in category 1 of FDA's interim policy for bulk drug substances nominated for use by state-licensed pharmacies and physicians [1][3]. Category 1 means GHK-Cu was nominated with sufficient supporting information for FDA to evaluate it, and FDA generally does not intend to take action against a compounder if the policy conditions are met [3].

The listing has changed. GHK-Cu was removed from category 1 on April 22, 2026, when the nominations were withdrawn. On May 5, 2026, a nominator clarified that only the injectable route had been withdrawn, and FDA added non-injectable GHK-Cu back; the list was updated May 14, 2026 [1][3].

FDA says it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 about whether GHK-Cu belongs on the pharmacy bulks list. No vote has happened [1]. GHK-Cu is not among the six peptides named in HHS's October 2026 draft enforcement-discretion policy [10], and it does not appear on FDA's list of bulk substances for outsourcing facilities updated March 21, 2025 [11].

The injectable form is where FDA names a risk

FDA's page on bulk substances that may present significant safety risks, content dated 04/22/2026, lists 'GHK-Cu (for injectable routes of administration)' in its table of substances nominated but withdrawn [4]. The agency's stated concern: 'Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations' [4]. Injectable GHK-Cu is not in category 1 and does not appear in any category on FDA's current list [1].

What the human data actually show

Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [12]. For GHK-Cu specifically, the human literature is small and almost entirely topical.

A randomized trial published in 2006 tested a copper tripeptide complex on skin resurfaced with a CO2 laser. Thirteen patients completed it. Computer analysis and blinded evaluators found no significant difference in how quickly redness resolved, or in wrinkles or overall skin quality. A patient questionnaire did show a significant difference in overall skin quality favoring GHK-Cu (P=.04) [6].

A randomized evaluator-blinded trial published in 1992 compared a 0.4% tripeptide copper complex cream with an inert vehicle in 86 evaluable patients with venous stasis ulcers. The copper cream was no different from the vehicle; silver sulfadiazine 1% reduced ulcer size [5].

A 2026 systematic review screened 1,247 records and retained 64, concluding that despite four decades of preclinical work the human literature remains thin and fragmented, with most randomized trials small and run on facial cosmetic creams. The authors note that microneedle delivery of GHK-Cu has not been evaluated in a single registered, adequately powered human randomized trial [13].

The healing effects in dogs, rats, mice and pigs, and the effects on collagen and metalloproteinase activity, come from laboratory and animal work summarized by the researchers who proposed them. These are proposed mechanisms, not proven human effects [14].

What about copper?

GHK-Cu is the copper(II) complex of the tripeptide GHK [14]. No FDA-approved drug is known to contain it, so no approved label sets a copper threshold for it. The label of cupric chloride injection, a copper additive for intravenous nutrition and a different product, gives normal serum copper values of 80 to 163 mcg/dL (mean about 110 mcg/dL) and states that copper is mainly eliminated in bile and is not reabsorbed from the gastrointestinal tract. It also says copper accumulates in the liver in cholestasis or cirrhosis, that copper given to a patient with Wilson disease may increase hepatic accumulation and aggravate hepatocellular degeneration, and that acute copper toxicity has been reported after oral, intravenous or subcutaneous exposure [15]. Those findings come from a different product and are not evidence of GHK-Cu-specific toxicity.